Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Propanc Biopharma, Inc. - Common Stock (NQ:PPCB)

0.8505 +0.0192 (+2.31%)
Streaming Delayed Price Updated: 10:47 AM EST, Dec 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Propanc Biopharma, Inc. - Common Stock

News headline image
Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs
Joint Research Team Focusing on Impact of PRP Reversal of EMT Pathways as Central Role 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline
Initial Investment of $1 Million Received from Hexstone Capital LLC Upon Closing 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
Initial Conversion Price of $5.00 Per Share Representing a 280% Premium Over the Company’s Recent Closing Price of $1.78 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
Initial Conversion Price of $5.00 Per Share Representing a 280% Premium Over the Company’s Recent Closing Price of $1.78 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy
From Propanc Biopharma, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.